ConductScience.org, home

Library / Trial comparisons

Atomoxetine vs Matching Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 1000.161wilsonClinicalTrials.gov
Risk in group 20.150.05240.36wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.15-0.360.0384newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 2loga group has no participants with the outcomeClinicalTrials.gov
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zeroClinicalTrials.gov
Number needed to treat, for one fewer participant with a serious adverse event on Atomoxetine than on Matching Placebo6.67from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1AtomoxetineIndividuals in this arm received 40 milligram twice a day atomoxetine.020EG000ClinicalTrials.gov
Group 2Matching PlaceboIndividuals in this arm received twice a day matching placebo.320EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, serious adverse eventsClinicalTrials.gov
Time frameAdverse events were reported from September 2006 through November 2007 (14.3 months)ClinicalTrials.gov

Trial 8

FieldValueSource
TitleAtomoxetine and Huntington's DiseaseClinicalTrials.gov
NCT numberNCT00368849ClinicalTrials.gov
PhasesPHASE2ClinicalTrials.gov
ConditionsHuntington Disease, ChoreaClinicalTrials.gov
Interventionsatomoxetine, Matching PlaceboClinicalTrials.gov
Lead sponsorUniversity of IowaClinicalTrials.gov
Results first posted2012-11-27ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00368849?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.